Bio News
Germany-based Boehringer Ingelheim has entered into a multiyear oncology collaboration with U.S.-based Envisagenics worth up to $1 billion (approximately 1.34 trillion won).
Boehringer Ingelheim will use Envisagenics’ artificial intelligence platform, SpliceCore, to validate tumor-specific targets.
Envisagenics plans to use the upfront payment and milestone payments from the agreement to advance its central nervous system candidates into clinical development.
BIOBOOK TEAM
biobookmedia@biobook.co.krKorea National Park Service Uses AI to Identify 17 Wildlife Species, Cuts Analysis Time by 99%
Ipscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Korea National Park Service Uses AI to Identify 17 Wildlife Species, Cuts Analysis Time by 99%
Ipscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
